A combination regimen by lopinave/litonawe (LPV/r), emtricitabine and tenofovir alafenamide fumarate (FTC/TAF) for treatment of novel coronavirus pneumonia (TARCoV)/ 中华急诊医学杂志

Q4 Nursing

中华急诊医学杂志 Pub Date : 2020-02-10 DOI:10.3760/CMA.J.ISSN.1671-0282.2020.03.003

Hua Jiang, Yu Wang, Kai Wang, Xingxiang Yang, Jian-cheng Zhang, Hongfei Deng, Lu Wang, J. Zeng

{"title":"A combination regimen by lopinave/litonawe (LPV/r), emtricitabine and tenofovir alafenamide fumarate (FTC/TAF) for treatment of novel coronavirus pneumonia (TARCoV)/ 中华急诊医学杂志","authors":"Hua Jiang, Yu Wang, Kai Wang, Xingxiang Yang, Jian-cheng Zhang, Hongfei Deng, Lu Wang, J. Zeng","doi":"10.3760/CMA.J.ISSN.1671-0282.2020.03.003","DOIUrl":null,"url":null,"abstract":"Objective \nTo explore the efficacy of a combination regimen by Lopinave/Litonawe (LPV/r), emtricitabine and tenofovir alafenamide fumarate (FTC/TAF) for the treatment of novel coronavirus pneumonia (NCP). \n \n \nMethods \nWe design the protocol as a real world study, which includes two groups: prospective intervention cohort (T1) and historical control group (T2). For T1 group, ninety patients will be enrolled who are diagnosed as NCP. All patients in T1 group will receive standard therapies following the recommendation in the guidelines of National Commission of Health, and they will be administered an anti-virus regimen includes LPV/r and FTC/TAF. The T2 group will enroll patients who have received single regimen includes LPV/r. The major outcome is the survival rate of patients. Secondary outcomes are the time of seroconversion of RNA, ARDS progression rate and length of hospital stay. \n \n \nConclusions \nThe results of this real world study might provide clinical practitioners a high efficiency and fast antivirus regimen for NCP. In addition, the conduction of this study will accelerate screening for other new effective therapeutic method. \n \n \nKey words: \nNovel coronavirus pneumonia; Lopinave/Litonawe; Emtricitabine and tenofovir alafenamide fumarate; Survival rate; Length of hospital stay","PeriodicalId":9981,"journal":{"name":"中华急诊医学杂志","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华急诊医学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1671-0282.2020.03.003","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Nursing","Score":null,"Total":0}

引用次数: 2

Abstract

Objective To explore the efficacy of a combination regimen by Lopinave/Litonawe (LPV/r), emtricitabine and tenofovir alafenamide fumarate (FTC/TAF) for the treatment of novel coronavirus pneumonia (NCP). Methods We design the protocol as a real world study, which includes two groups: prospective intervention cohort (T1) and historical control group (T2). For T1 group, ninety patients will be enrolled who are diagnosed as NCP. All patients in T1 group will receive standard therapies following the recommendation in the guidelines of National Commission of Health, and they will be administered an anti-virus regimen includes LPV/r and FTC/TAF. The T2 group will enroll patients who have received single regimen includes LPV/r. The major outcome is the survival rate of patients. Secondary outcomes are the time of seroconversion of RNA, ARDS progression rate and length of hospital stay. Conclusions The results of this real world study might provide clinical practitioners a high efficiency and fast antivirus regimen for NCP. In addition, the conduction of this study will accelerate screening for other new effective therapeutic method. Key words: Novel coronavirus pneumonia; Lopinave/Litonawe; Emtricitabine and tenofovir alafenamide fumarate; Survival rate; Length of hospital stay

查看原文本刊更多论文

洛匹那韦/利托那韦（LPV/r）、恩曲他滨和富马酸替诺福韦艾拉酚胺（FTC/TAF）联合方案治疗新型冠状病毒肺炎（TARCoV）/中华急诊医学杂志

目的探讨洛匹纳韦/利托纳韦(LPV/r)、恩曲他滨和富马酸替诺福韦(FTC/TAF)联合治疗新型冠状病毒肺炎(NCP)的疗效。方法我们设计了一项真实世界的研究方案，包括两组:前瞻性干预组(T1)和历史对照组(T2)。T1组纳入90例确诊为新型冠状病毒感染的患者。T1组所有患者均按照国家卫生健康委员会指南建议接受标准治疗，给予LPV/r和FTC/TAF抗病毒方案。T2组将纳入接受包括LPV/r的单一方案的患者。主要的结果是患者的存活率。次要观察指标为血清RNA转化时间、ARDS进展率和住院时间。结论本研究结果可为临床提供一种高效、快速的新型冠状病毒抗病毒方案。此外，本研究的开展将加速其他新的有效治疗方法的筛选。关键词:新型冠状病毒肺炎;Lopinave / Litonawe;恩曲他滨和富马酸替诺福韦;存活率;住院时间

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

中华急诊医学杂志 Nursing-Emergency Nursing

CiteScore

0.10

自引率

0.00%

发文量

8629

期刊介绍： Chinese Journal of Emergency Medicine is the only national journal which represents the development of emergency medicine in China. The journal is supervised by China Association of Science and Technology, sponsored by Chinese Medical Association, and co-sponsored by Zhejiang University. The journal publishes original research articles dealing with all aspects of clinical practice and research in emergency medicine. The columns include Pre-Hospital Rescue, Emergency Care, Trauma, Resuscitation, Poisoning, Disaster Medicine, Continuing Education, etc. It has a wide coverage in China, and builds up communication with Hong Kong, Macao, Taiwan and international emergency medicine circles.